Alzheimer’s disease is a growing burden, and a number of clinical failures to treat the neurodegenerative disease have basic and preclinical scientists thinking about how best to actually model such a complicated condition in animals. Many clinicians and researchers are starting to recognize that there’s likely not one definition of Alzheimer’s disease in people and as such, there likely won’t be one best animal model either.

Our September feature story considers some new approaches, from introducing genetic diversity into what have traditionally been rather homogenous mouse studies, to watching our closest relatives as they age naturally for signs and symptoms that might translate to humans, to looking beyond mammals entirely for drug and target screening.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD